2018
DOI: 10.1128/aac.00956-18
|View full text |Cite
|
Sign up to set email alerts
|

Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients

Abstract: Methicillin-resistant Staphylococcus aureus (MRSA) acquisition in cystic fibrosis (CF) patients confers a clinical outcome worse than that in non-CF patients with an increased rate of declined lung function. Telavancin, an approved lipoglycopeptide used to treat infections due to S. aureus, has a dual mode of action causing inhibition of peptidoglycan synthesis and membrane depolarization.

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2019
2019
2021
2021

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 28 publications
0
2
0
Order By: Relevance
“…Although neither 10 mg/kg nor higher doses of 12.5 mg/kg or 750 mg achieved optimal PTA for those MICs above the susceptibility breakpoint in adults with CF, this is unlikely to be clinically relevant. In a collection of 333 S. aureus strains cultured from patients with CF, 100% had a telavancin MIC of less than or equal to 0.06 mg/liter (28), which a 10-mg/kg dose is predicted to adequately treat even if any of these MICs were underestimated by 1 doubling dilution. Attempts to overcome telavancin resistance (MIC Ͼ 0.12 mg/liter) by using doses above 12.5 mg/kg would necessarily increase the chances of reaching the toxicity threshold AUC of 763 mg • h • liter Ϫ1 associated with AKI beyond 12.2% (17), creating an unacceptable risk of a serious adverse event while providing little to no benefit.…”
Section: Discussionmentioning
confidence: 99%
“…Although neither 10 mg/kg nor higher doses of 12.5 mg/kg or 750 mg achieved optimal PTA for those MICs above the susceptibility breakpoint in adults with CF, this is unlikely to be clinically relevant. In a collection of 333 S. aureus strains cultured from patients with CF, 100% had a telavancin MIC of less than or equal to 0.06 mg/liter (28), which a 10-mg/kg dose is predicted to adequately treat even if any of these MICs were underestimated by 1 doubling dilution. Attempts to overcome telavancin resistance (MIC Ͼ 0.12 mg/liter) by using doses above 12.5 mg/kg would necessarily increase the chances of reaching the toxicity threshold AUC of 763 mg • h • liter Ϫ1 associated with AKI beyond 12.2% (17), creating an unacceptable risk of a serious adverse event while providing little to no benefit.…”
Section: Discussionmentioning
confidence: 99%
“… 1 , 2 Despite the continuous improvement of effective antimicrobial and patient care conditions, many cases of S. aureus bacteremia or sepsis with significant morbidity and mortality have been reported worldwide. 3 , 4 With the widespread use or even misuse of antibacterial agents, S. aureus has shown the resistance to a broad range of antibiotics, such as vancomycin and daptomycin. In particular, the widespread emergence of multidrug-resistant S. aureus and methicillin-resistant S. aureus (MRSA) has resulted in a limited number of therapeutic options against S. aureus infections increasingly.…”
Section: Introductionmentioning
confidence: 99%